Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fexofenadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 0.73 |
| ▸ | LMNA | P02545 | 5/20 | 0.73 |
| ▸ | DRD3 | P35462 | 3/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.73 |
| ▸ | BLM | P54132 | 3/20 | 0.73 |
| ▸ | HTR2A | P28223 | 2/20 | 0.73 |
| ▸ | HTR2B | P41595 | 2/20 | 0.73 |
| ▸ | CNR1 | P21554 | 1/20 | 0.73 |
| ▸ | APEX1 | P27695 | 1/20 | 0.73 |
| ▸ | PDE4A | P27815 | 1/20 | 0.73 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.73 |
| ▸ | DRD2 | P14416 | 2/20 | 0.72 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.72 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terfenadine SCHEMBL8887396 | 0.87 | LMNA (0.59) | LMNAHRH1DRD3KCNH2BLM | |
| Terfenadine SCHEMBL3654979 | 0.86 | KCNH2 (0.61) | LMNAHRH1DRD3KCNH2BLM | |
| Fexofenadine SCHEMBL1649976 | 0.85 | HRH1 (0.96) | LMNAHRH1DRD3KCNH2BLM | |
| Fexofenadine SCHEMBL3543634 | 0.85 | HRH1 (0.98) | LMNAHRH1DRD3KCNH2BLM | |
| Fexofenadine SCHEMBL1972366 | 0.85 | HRH1 (1.00) | LMNAHRH1DRD3KCNH2BLM | |
| Fexofenadine SCHEMBL1561082 | 0.85 | HRH1 (1.00) | LMNAHRH1DRD3KCNH2BLM | |
| Fexofenadine SCHEMBL4901 | 0.85 | HRH1 (1.00) | LMNAHRH1DRD3KCNH2BLM | |
| Fexofenadine SCHEMBL4900 | 0.85 | HRH1 (1.00) | LMNAHRH1DRD3KCNH2BLM | |
| Fexofenadine SCHEMBL3178320 | 0.85 | HRH1 (1.00) | LMNAHRH1DRD3KCNH2BLM | |
| Fexofenadine SCHEMBL7104316 | 0.85 | HRH1 (1.00) | LMNAHRH1DRD3KCNH2BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240075049-A1 | DRUGS, THERAPEUTIC COMBINATIONS AND METHODS FOR PREVENTING VIRAL AND MICROBIAL INFECTIONS AND THEIR SEQUELAE | TOPELIA AUST LTD ACN 652 771 670 (AU) | 2024-03-07 | — | — | US | claimed |
| US-20240181023-A1 | FUNCTIONALIZED BIOCATALYTICAL COMPOSITIONS | PERSEO PHARMA AG (CH) | 2024-06-06 | — | — | US | disclosed |
| WO-2024061861-A1 | FUNCTIONALIZED BIOCATALYTICAL COMPOSITIONS | PERSEO PHARMA AG (CH) | 2024-03-28 | — | — | WO | disclosed |
| EP-4326228-A1 | FUNCTIONALIZED BIOCATALYTICAL COMPOSITIONS | Perseo Pharma AG (CH) | 2024-02-28 | — | — | EP | disclosed |
| US-11857617-B2 | Methods for treating, ameliorating or preventing infections using drug and vaccination combination treatment | TOPELIA AUST LIMITED (652 771 670) (AU) | 2024-01-02 | — | — | US | disclosed |
| US-20210330635-A1 | THERAPEUTIC COMPOSITIONS, PRODUCTS OF MANUFACTURE AND METHODS FOR AMELIORATING OR PREVENTING CORONAVIRUS INFECTION | TOPELIA AUST LIMITED (652 771 670) (AU) | 2021-10-28 | — | — | US | disclosed |
| US-20210244705-A1 | THERAPEUTIC COMPOSITIONS, PRODUCTS OF MANUFACTURE AND METHODS FOR AMELIORATING OR PREVENTING CORONAVIRUS INFECTION | TOPELIA AUST LIMITED (652 771 670) (AU) | 2021-08-12 | — | — | US | disclosed |
| US-20130143869-A1 | USE OF A CATIONIC AMPHIPHILIC DRUG FOR THE PREPARATION OF A FORMULATION FOR THE REDUCTION OF SUBCUTANEOUS ADIPOSE TISSUE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2013-06-06 | — | — | US | disclosed |
| EP-2593093-A1 | USE OF A CATIONIC AMPHIPHILIC DRUG FOR THE PREPARATION OF A FORMULATION FOR THE REDUCTION OF SUBCUTANEOUS ADIPOSE TISSUE | Merz Pharma GmbH & Co. KGaA (DE) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007560-A1 | USE OF A CATIONIC AMPHIPHILIC DRUG FOR THE PREPARATION OF A FORMULATION FOR THE REDUCTION OF SUBCUTANEOUS ADIPOSE TISSUE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240075049-A1 | DRUGS, THERAPEUTIC COMBINATIONS AND METHODS FOR PREVENTING VIRAL AND MICROBIAL INFECTIONS AND THEIR SEQUELAE | ACE, ACHE, SARS1 | HRH1 2890/4885LMNA 1046/4885DRD3 1583/4885 |
| US-11857617-B2 | Methods for treating, ameliorating or preventing infections using drug and vaccination combination treatment | ZFX, IKZF3, ACE2 | HRH1 4729/4885LMNA 4341/4885DRD3 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.